MARKET

XBIO

XBIO

Xenetic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.860
+0.020
+1.09%
After Hours: 1.830 -0.03 -1.61% 16:28 05/07 EDT
OPEN
1.820
PREV CLOSE
1.840
HIGH
2.020
LOW
1.790
VOLUME
218.66K
TURNOVER
--
52 WEEK HIGH
5.85
52 WEEK LOW
0.7600
MARKET CAP
16.27M
P/E (TTM)
-1.0818
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers  
Benzinga · 5d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 04/27 20:57
Gold Fields, Danimer Scientific among premarket losers' pack
AeroCentury (ACY) -46% after filing petition for Chapter 11Wave Life Sciences (WVE) -27% on setback for Huntington’s disease trial (updated).Trxade Group (MEDS) -21% on Q4 earnings release.Vinco Ventures (BBIG) -16% on providing update to ZASH Global Media...
Seekingalpha · 03/30 12:42
Xenetic Biosciences shares rise on approval to start XCART exploratory study
Xenetic Biosciences (XBIO) has received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens.Shares up nearly 13%...
Seekingalpha · 03/29 12:39
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)
\- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States\- Study will evaluate the XCART process of neoantigen identifica...
ACCESSWIRE · 03/29 12:05
Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results
* Driving development of XCART™ platform and leveraging academic collaborations through preclinical development * Recent clinical, regulatory and commercial advancements from licensing partners leveraging PolyXen® platform technology FRAMINGHAM, MA / ACCES...
ACCESSWIRE · 03/17 13:00
H.C. Wainwright Sticks to Its Buy Rating for Xenetic Biosciences (XBIO)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xenetic Biosciences (XBIO), with a price target of $5.00. The
SmarterAnalyst · 03/17 10:26
10-K: XENETIC BIOSCIENCES, INC.
Edgar Online - (EDG = 10Q, 10K) · 03/16 21:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XBIO. Analyze the recent business situations of Xenetic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XBIO stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 17
Institutional Holdings: 302.54K
% Owned: 3.46%
Shares Outstanding: 8.75M
TypeInstitutionsShares
Increased
1
110.99K
New
4
104.50K
Decreased
0
0
Sold Out
2
12.40K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chief Executive Officer/Chief Operating Officer/Director
Jeffrey Eisenberg
Chief Financial Officer/Chief Accounting Officer
James Parslow
Chief Scientific Officer
Curtis Lockshin
Treasurer/Secretary/Director
Colin Hill
Director
Grigory Borisenko
Director
Timothy Cote
Director
Firdaus Dastoor
Director
Artur Isaev
Director
Roger Kornberg
Independent Director
James Callaway
Independent Director
Dmitry Genkin
Independent Director
Adam Logal
No Data
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The Company is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties.

Webull offers kinds of Xenetic Biosciences Inc stock information, including NASDAQ:XBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIO stock methods without spending real money on the virtual paper trading platform.